AI Bias Analysis
4 models · Takes ~15 seconds
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
Source
Stat News
Opens original article in a new tab
(MedPage Today) -- CHICAGO -- A paradigm-changing clinical trial in prostate cancer showed that perioperative apalutamide (Erleada) and androgen deprivation therapy (ADT) significantly reduced the risk of metastasis in high-risk localized disease...
(MedPage Today) -- "The light goes out of their eyes in about 3 years. This is not what they signed up for." -- Clark Coler, MD, of Swedish Medical Group in Seattle, on young physicians facing the increasingly profit-driven demands of modern...
(MedPage Today) -- CHICAGO -- A first-in-class bispecific antibody targeting PD-1 and VEGF combined with chemotherapy significantly improved overall survival (OS) in patients with advanced squamous non-small cell lung cancer (NSCLC), according...
(MedPage Today) -- Donald Trump's physician says the president is in "excellent health" and is "fully fit" to serve as commander in chief after a medical exam Tuesday at Walter Reed National Military Medical Center that showed the president's body...
